Liver Fibrosis Progression and Mortality in Hepatitis B– and C–Coinfected Persons Treated With Directly Acting Antiviral Agents: Results From ERCHIVES. (16th December 2019)

• Record Type: Journal Article
• Authors: Butt, Adeel A; Yan, Peng; Aslam, Samia; Abou-Samra, Abdul-Badi; Sherman, Kenneth E; Shaikh, Obaid S
• Is Part Of: Clinical infectious diseases. Volume 71:Number 3(2020)
• Page Start: 664
• Page End: 666
• Publication Date: 2019-12-16
• Subjects: HCV -- HBV -- HCV/HBV coinfection -- fibrosis progression -- ERCHIVES; Communicable diseases -- Periodicals; 616.905
• DOI: 10.1093/cid/ciz1097
• Languages: English
• ISSNs: 1058-4838

Abstract

Abstract: For persons with baseline Fibrosis-4 1.46–3.25, cirrhosis incidence/1000 patient-years was 49.3 among hepatitis B virus (HBV)/hepatitis C virus (HCV) coinfected and 18.2 among HCV monoinfected ( P = .03). Cirrhosis risk was numerically higher but statistically nonsignificant among HBV/HCV coinfected (hazards ratio [HR] 1.51; 95% confidence intervals [CI], .37–6.05) but lower among those who attained sustained virologic response (HR, .52; 95% CI, .42–.63).